Search Results
REACH2: What patients with steroid-refractory acute GvHD respond best to ruxolitinib?
Case 2: Ruxolitinib for Steroid-Refractory Acute GVHD
Case 3: Ruxolitinib for Steroid-Refractory Acute GVHD
REACH2 study: What is the risk of losing response to ruxolitinib over time?
Overcoming the Challenges of Acute and Chronic GVHD
Case 2: Treating Steroid-Refractory Acute GVHD
Case 2: Treating Steroid-Refractory Acute Graft-Versus-Host Disease
Updates on REACH2: ruxolitinib vs BAT for SR-aGvHD
REACH3 study: Should ruxolitinib become SoC for steroid-dependent or refractory chronic GvHD?
Unmet needs in SR-aGvHD and TR-aGvHD
Advantages and limitations of ruxolitinib for cGvHD
Ruxolitinib Used to Prevent GVHD Throughout Stem Cell Transplantation
